Sales of a generic version of blood thinner Plavix that began 10 days ago must be stopped or the incentive for researchers to make pioneering medical breakthroughs will be ruined, a lawyer for the drug's maker warned a judge Friday. "You can never put this Humpty-Dumpty back together if it's not stopped," attorney Evan Chessler said on behalf of Sanofi-Aventis SA, which sells Plavix with partner Bristol-Myers Squibb Co, at the start of a two-day hearing to decide whether the Aug. 8 launch of a drug by Apotex Inc. should be stopped. Chessler said Apotex flooded the market with its product, already driving down prices. "It will kill future clinical efforts," he told U.S. District Judge Sidney H. Stein as he urged the judge to hastily stop Apotex and force the company to recall supplies of the drug it has already sold.